Live Price Coverage: Could Bovie Medical Corporation Lose its Strength? The Stock Reaches 52-Week High

Live Price Coverage: Could Bovie Medical Corporation Lose its Strength? The Stock Reaches 52 Week High

The stock of Bovie Medical Corporation (NYSEMKT:BVX) hit a new 52-week high and has $14.95 target or 182.00% above today’s $5.30 share price. The 9 months bullish chart indicates low risk for the $160.11 million company. The 1-year high was reported on Oct, 3 by Barchart.com. If the $14.95 price target is reached, the company will be worth $291.40 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 47,885 shares traded hands. Bovie Medical Corporation (NYSEMKT:BVX) has risen 175.66% since February 29, 2016 and is uptrending. It has outperformed by 163.45% the S&P500.

Analysts await Bovie Medical Corporation (NYSEMKT:BVX) to report earnings on November, 2. They expect $-0.03 EPS, up 57.14% or $0.04 from last year’s $-0.07 per share. After $-0.02 actual EPS reported by Bovie Medical Corporation for the previous quarter, Wall Street now forecasts 50.00% negative EPS growth.

According to Zacks Investment Research, “Bovie Medical Corporation, formerly An-Con Genetics Inc., is engaged in the manufacturing and marketing of a diverse line of medical devices and advanced coating technologies.”

Insitutional Activity: The institutional sentiment decreased to 0.54 in 2016 Q2. Its down 0.60, from 1.14 in 2016Q1. The ratio is negative, as 7 funds sold all Bovie Medical Corporation shares owned while 6 reduced positions. 2 funds bought stakes while 5 increased positions. They now own 4.70 million shares or 6.35% less from 5.02 million shares in 2016Q1.
California Pub Employees Retirement accumulated 0% or 28,177 shares. Renaissance Techs Ltd Llc last reported 149,600 shares in the company. The Minnesota-based Perkins Capital Inc has invested 0.67% in Bovie Medical Corporation (NYSEMKT:BVX). Moreover, Northern Tru has 0% invested in Bovie Medical Corporation (NYSEMKT:BVX) for 54,945 shares. Blackrock Investment Mgmt Limited Liability owns 4,801 shares or 0% of their US portfolio. Great Point Prtn Limited Liability has 2.68 million shares for 1.26% of their US portfolio. Geode Capital Mngmt Ltd Limited Liability Company reported 73,582 shares or 0% of all its holdings. Vanguard Group Inc accumulated 540,757 shares or 0% of the stock. Bancorp Of America De holds 102 shares or 0% of its portfolio. Creative Planning has invested 0% of its portfolio in Bovie Medical Corporation (NYSEMKT:BVX). Wasatch Advisors Inc has invested 0.01% of its portfolio in Bovie Medical Corporation (NYSEMKT:BVX). Deutsche Commercial Bank Ag holds 250 shares or 0% of its portfolio. Blackrock Institutional Na has 12,139 shares for 0% of their US portfolio. Salem Counselors reported 29,771 shares or 0.01% of all its holdings. Kennedy Mngmt holds 0% or 29,179 shares in its portfolio.

Insider Transactions: Since August 17, 2016, the stock had 1 insider buy, and 0 insider sales for $299,475 net activity. On Wednesday, August 17 the insider McCarthy John J. III bought $299,475.

More recent Bovie Medical Corporation (NYSEMKT:BVX) news were published by: Marketwatch.com which released: “Bovie Medical Corp. NYSE MKT: BVX” on November 10, 2010. Also Businesswire.com published the news titled: “Bovie Medical Corporation Reports Second Quarter and First Half 2016 Results” on August 01, 2016. Businesswire.com‘s news article titled: “Bovie Medical Corporation Hires J-Plasma Product Development Manager” with publication date: May 26, 2015 was also an interesting one.

BVX Company Profile

Bovie Medical Corporation (Bovie), incorporated on December 3, 1982, is an energy medical device company. The Firm is also engaged in the design, development and manufacturing of electrosurgical equipment by producing equipment for medical device manufacturers through original equipment manufacturing (OEM) agreements, as well as start-up companies. The Firm operates through three divisions: Core, OEM and J-Plasma. The Firm is engaged in developing, manufacturing and marketing a range of electrosurgical products and technologies, as well as related medical products used in doctor’s offices, surgery centers and hospitals around the world. It also develops J-Plasma, a helium plasma surgical product. The J-Plasma system consists of an electrosurgical generator unit (ESU), a handpiece and a supply of helium gas. The Company’s medical devices are marketed through its own brands, including Bovie, Aaron, DERM, IDS and ICON, and on a private label basis to distributors around the world. The Firm offers its products in three categories: electrosurgery, cauteries and other products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment